FDA approves maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

On March 27, the U.S. Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors responded completely or partially to platinum-based chemotherapy. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here